Mup Study Group 1996.
| Methods | Double‐blind, randomised controlled trial | |
| Participants | CAPD patients. All carriers. Mupirocin: 134. Placebo: 133. No significant difference between both groups. | |
| Interventions | Mupirocin or placebo. Twice daily for 5 days every 4 weeks, for maximal 18 months. | |
| Outcomes | S. aureus infection rate. Mortality. Adverse events. Infection rate caused by other micro‐organisms than S. aureus. | |
| Notes | This study was sponsored by the manufacturers of mupirocin (SmithKline Beecham, Baxter Health Care) | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment? | Unclear risk | Unclear |
| Blinding? participants | Low risk | |
| Blinding? outcome assessor | Low risk | |
| Intention to treat | Low risk | reported and confirmed |
| Loss to follow up | Low risk | Mupirocin:1 Placebo:1 |